Abstract
Objective: To assess the effect of add-back therapy with continuous combined estrogen-progestin on the GnRH agonist–induced hypoestrogenic state and its effectiveness in healing of endometriotic lesions. Design: A prospective, randomized, placebo-controlled, double-blind trial. Setting: Multiple centers in The Netherlands. Patient(s): 41 premenopausal women with laparoscopically diagnosed endometriosis (revised American Fertility Society scores ≥2). Intervention(s): Patients were randomly assigned to receive a subcutaneous depot formulation of goserelin, 3.6 mg, every 4 weeks, plus oral placebo or oral continuous combined estradiol-norethisterone acetate add-back therapy daily for 24 weeks. Main Outcome Measure(s): Endometriosis response, bone mineral density, transvaginal ultrasonographic changes, endocrinologic effects, and subjective side effects. Result(s): The number of endometriotic implants was significantly reduced in both groups. In the group that received GnRH agonist plus placebo, bone mineral density of the lumbar spine decreased by 5.02%. Conclusion(s): The effectiveness of GnRH agonist treatment for endometriosis was not decreased by the addition of add-back continuous combined hormone replacement therapy. Bone mineral density of the lumbar spine was maintained and subjective side effects were diminished.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.